

Cover Story
By Matthew Bin Han Ong
In the next few weeks, FDA will announce its decision on Novartis's Zarxio, a granulocyte-colony stimulating factor biosimilar to Amgen's Neupogen.
By Matthew Bin Han Ong
By Matthew Bin Han Ong
In Brief
Funding Opportunities
Drugs & Targets
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- A new AI tool enables speedy use of ASCO guidelines, eliminating typical errors
- KRAS pioneer and Stephenson Prize winner Frank McCormick aims to prevent all KRAS cancers with a pill
- Brian Wolpin celebrates FDA approval of daraxonrasib in pancreatic cancer as the future of the field













